Expand your market reach with Tris’ innovative technologies
Open up new market segments by offering sustained release products in alternative dosage forms for patients having difficulty swallowing pills. Our innovative OralXR+ technology offers sustained release in a variety of dosage forms such as liquid, chewable tablets, strips and ODT.
Protect your products from intentional and unintentional abuse
Nobuse™ is an abuse resistant proprietary technology applicable to all controlled substances and opiates for all oral dosage forms in immediate and sustained release versions.
News & Events |
FDA accepts CCP-07 NDA for full review (September 2016) Read More
Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD (April 2016) Read More
Tris Pharma Announces Appointment of Chief Commercial Officer of its New Brand Business (April 2016) Read More
Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet (December 2015) Read More
Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII (December 2015) Read More
Tris Pharma Receives FDA Approval of Dyanavel™ XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children (October 2015) Read More
Tris Pharma Launches Generic Tussionex® as Par's Rights Expire (October 2015) Read More
Vernalis PLC launches Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing (September 2015) Read More
FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children (August 2015) Read More
Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand (June 2015) Read More
Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel™ XR (May 2015) Read More
Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR (May 2015) Read More
FDA accepts Tuzistra™ XR (CCP-01) NDA for full review (September 2014) Read More
Tris Pharma Receives NJBIA Award for Excellence Read More
Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept Read More
Submission of TuzistraTM XR (CCP-01) NDA to FDA Read More
Tris Pharma Expands R&D Team with addition of Chief Medical Officer and Vice President of Regulatory Affairs Read More
Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept Read More
Tris Pharma Announces Management Changes Read More
Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 Read More
Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension Read More
Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution Read More
Tris Pharma Hires President for Generic Pharmaceuticals Business Read More
Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey Read More
FDA Approves Tris Pharma’s New Drug Application for KarbinalTM ER (carbinoxamine maleate) Extended-release Oral Suspension Read More
First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris Read More
Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States Read More
Tris Pharma Appoints New Vice President of Business Development (November 2012) Read More
Pfizer To Acquire NextWave Pharmaceuticals, Inc. (October 2012) Read More
NextWave Pharmaceuticals Receives FDA Approval of Quillivant XR™ for Once-Daily Treatment of ADHD (October 2012) Read More
Perrigo and Tris Pharma launch store brand version of Delsym® (August 2012) Read More
Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals (July 2012) Read More
Tris Pharma to Hold Job Fairs - Saturday June 16 and Saturday June 23 (June 2012) Read More
Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension (May 2012) Read More
Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension (May 2012) Read More
Tris Pharma Announces Management Additions, Promotion (April 2012) Read More
Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market (February 2012) Read More
Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive (January 2012) Read More
Tris Pharma Announces US Patent Grant Covering Platform Technology (January 2012) Read More
Tris Pharma Expands Leadership Team, Adds Senior Managers in Quality and Finance (August 2011) Read More
Extend your power to innovate
As a pioneer in the development of sustained release oral dosage forms, we dream big, never give up and relish in solving the unsolvable... Read More
